Core Viewpoint - The National Healthcare Security Administration has announced that certain pharmaceutical companies will have their drug procurement qualifications suspended starting from September 16, 2025, due to non-compliance with drug price adjustment requirements [1]. Group 1: Drug Procurement Suspension - The suspension affects specific drugs from various manufacturers, including Staidson (Beijing) BioPharmaceuticals Co., Ltd., which produces Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder [5][9]. - The list of drugs affected by the procurement suspension includes various formulations and dosages, indicating a broad impact across multiple products [3][4]. Group 2: Company Information - Staidson (Beijing) BioPharmaceuticals Co., Ltd. was established in August 2002 and was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on April 15, 2011, with the stock code 300204 [7][10]. - The company is currently discussing the implications of the procurement suspension internally, as confirmed by their securities department [9].